



ZOETIS 2020 FINANCIAL HIGHLIGHTS

REVENUE BY SPECIES[†]




- Companion Animal 55%
- Cattle 24%
- Swine 10%
- Poultry 8%
- Fish 2%
- Sheep and other 1%

REVENUE BY PRODUCT CATEGORY[‡]




- Vaccines 22%
- Anti-Infectives 18%
- Parasiticides 18%
- Dermatology 14%
- Other Pharmaceuticals 13%
- Medicated Feed Additives 7%
- Animal Health Diagnostics 5%
- Other Non-Pharmaceuticals 3%

REVENUE BY TOP MARKETS[‡]




- United States 54%
- China 4%
- Brazil 4%
- Canada 3%
- Australia 3%
- United Kingdom 3%
- Japan 3%
- Germany 2%
- France 2%
- Mexico 2%
- Spain 2%
- Chile 1%
- Italy 1%
- Other emerging markets 10%
- Other developed markets 6%

REVENUE BY PRODUCT CONCENTRATION



- All Other 56%
- Top Ten Product Lines 44%

REVENUE GROWTH AND ADJUSTED EBIT MARGIN



○ Adjusted EBIT* Margin

* Adjusted EBIT (a non-GAAP financial measure) excludes interest expense net of capitalized interest, interest income and adjusted income taxes.

** Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income attributable to Zoetis and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items.

† Represents operational revenue growth (a non-GAAP financial measure), which is defined as revenue growth excluding the impact of foreign exchange. Reported revenue growth, including the impact of foreign exchange, was 10% for 2018, 7% for 2019 and 7% for 2020.

‡ Revenue charts exclude revenue associated with Client Supply Services and Human Health, which represented 1% of total 2020 revenue.

\$Millions (except per share data)

	2018	2019	2020
Revenue	\$ 5,825	\$ 6,260	\$ 6,675
Net Income Attributable to Zoetis	\$ 1,428	\$ 1,500	\$ 1,638
Adjusted Net Income Attributable to Zoetis**	\$ 1,525	\$ 1,755	\$ 1,844
Diluted Earnings Per Share	\$ 2.93	\$ 3.11	\$ 3.42
Adjusted Diluted Earnings Per Share**	\$ 3.13	\$ 3.64	\$ 3.85
Net Cash Provided by Operating Activities	\$ 1,790	\$ 1,795	\$ 2,126
Research & Development Expense	\$ 432	\$ 457	\$ 463